Advertisement

Complex Drug Interactions: Significance and Evaluation

  • Ping Zhao
  • Lei Zhang
  • Shiew-Mei Huang
Chapter

Abstract

Complex drug interactions that result from a multiplicity of factors (e.g., concomitant medications, organ dysfunction, genetic polymorphism of enzyme/transporter) may be accompanied by important clinical relevance. However, it is difficult to properly design and evaluate all possible complex drug interactions during drug development. In this chapter, we review the types of complex drug interactions and recent advances in studying complex drug interactions using modeling and simulation approaches. Challenges in the quantitative evaluation of complex drug interactions include (1) the need to understand metabolism/transport pathways and their interplay, (2) accurate assessment of key parameters (e.g., fractional clearance) at the enzyme/transporter level, and (3) knowledge in how altered physiological conditions (e.g., by disease states) affect drug disposition and response. Additional research will provide confidence in the use of modeling and simulation to guide clinical study design and generate data for the informative labeling and effective use of medications.

Keywords

Drug Interaction PBPK Model Drug Interaction Potential Drug Interaction Study Organ Impairment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Almond LM, Yang J, Jamei M, Tucker GT and Rostami-Hodjegan A (2009) Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab 10:420–432.Google Scholar
  2. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J and Wrighton SA (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–832.CrossRefPubMedGoogle Scholar
  3. Bouzom F and Walther B (2008) Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling. Funda Clin Pharmacol 22:579–587.CrossRefGoogle Scholar
  4. Brynne N, Forslund C, Hallen B, Gustafsson LL and Bertilsson L (1999) Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 48:564–572.CrossRefPubMedGoogle Scholar
  5. Chenel M, Bouzom F, Aarons L and Ogungbenro K (2008a) Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes. J Pharmacokinet Pharmacodyn 35:635–659.CrossRefPubMedGoogle Scholar
  6. Chenel M, Bouzom F, Cazade F, Ogungbenro K, Aarons L and Mentre F (2008b) Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results. J Pharmacokinet Pharmacodyn 35:661–681.CrossRefPubMedGoogle Scholar
  7. Chien JY, Lucksiri A, Ernest CS 2nd, Gorski JC, Wrighton SA and Hall SD (2006) Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos 34:1208–1219.CrossRefPubMedGoogle Scholar
  8. Clewell H and Andersen M (1996) Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 111:315–329.CrossRefPubMedGoogle Scholar
  9. Collins C, Levy R, Ragueneau-Majlessi I and Hachad H (2006) Prediction of maximum exposure in poor metabolizers following inhibition of nonpolymorphic pathways. Curr Drug Metab 7:295–299.CrossRefPubMedGoogle Scholar
  10. Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP and Maurel P (1989) Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 17:197–207.PubMedGoogle Scholar
  11. Covington T, Gentry P, Van Landingham C, Andersen M, Kester J and Clewell H (2007) The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. Regul Toxicol Pharmacol 47:1–18.CrossRefPubMedGoogle Scholar
  12. Dickins M and van de Waterbeemd H (2004) Simulation models for drug disposition and drug interactions. Drug Discov Today: Biosilico 2:38–45.CrossRefGoogle Scholar
  13. Dickinson GL, Lennard MS, Tucker GT and Rostami-Hodjegan A (2007a) The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. Br J Clin Pharmacol 64:14–26.CrossRefPubMedGoogle Scholar
  14. Dickinson GL, Rezaee S, Proctor NJ, Lennard MS, Tucker GT and Rostami-Hodjegan A (2007b) Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. J Clin Pharmacol 47:175–186.CrossRefPubMedGoogle Scholar
  15. Edginton A, Theil F, Schmitt W and Willmann S (2008) Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 4:1143–1152.CrossRefPubMedGoogle Scholar
  16. Edginton A and Willmann S (2008) Physiology-based simulations of a pathological condition prediction of pharmacokinetics in patients with liver cirrhosis. Clinical Pharmacokinet 47:743–752.CrossRefGoogle Scholar
  17. Einolf HJ (2007) Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257–1294.PubMedGoogle Scholar
  18. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA and Salazar DE (2007) Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 81:735–741.CrossRefPubMedGoogle Scholar
  19. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS and Shader RI (1999) Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 19:293–296.CrossRefPubMedGoogle Scholar
  20. Grime KH, Bird J, Ferguson D and Riley RJ (2009) Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 36:175–191.CrossRefPubMedGoogle Scholar
  21. Hack C, Chiu W, Zhao Q and Clewell H (2006) Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites. Regul Toxicol Pharmacol 46:63–83.CrossRefPubMedGoogle Scholar
  22. Hsu A, Granneman GR and Bertz RJ (1998) Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275–291.CrossRefPubMedGoogle Scholar
  23. Huang, S-M, Temple R, Xiao S, Zhang L, Lesko, LJ (2009) When to conduct a renal impairment study during drug development- US Food and Drug Administration perspective, Clin Pharmacol Ther In press.Google Scholar
  24. Huang SM, Lesko LJ and Temple R (2009a) Adverse drug reactions and pharmacokinetic drug interactions, in Fundamental principles: Clinical pharmacology. "Pharmacology and therapeutics: Principles to practice", Elsevier, Amsterdam.Google Scholar
  25. Huang SM and Temple R (2008) Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther 84:287–294.CrossRefPubMedGoogle Scholar
  26. Huang SM, Temple R, Throckmorton DC and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298–304.CrossRefPubMedGoogle Scholar
  27. Hyland R, Dickins M, Collins C, Jones H and Jones B (2008) Maraviroc: in vitro assessment of drug-drug interaction potential. Brit J Clin Pharmacol 66:498–507.CrossRefGoogle Scholar
  28. Isoherranen N, Kunze KL, Allen KE, Nelson WL and Thummel KE (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32:1121–1131.CrossRefPubMedGoogle Scholar
  29. Ito K, Hallifax D, Obach RS and Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837–844.CrossRefPubMedGoogle Scholar
  30. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387–412.PubMedGoogle Scholar
  31. Jamei M, Dickinson GL and Rostami-Hodjegan A (2009a) A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 24:53–75.CrossRefPubMedGoogle Scholar
  32. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G and Rostami-Hodjegan A (2009b) The Simcyp((R)) population-based ADME simulator. Expert Opin Drug Metab Toxicol 3:51–66.Google Scholar
  33. Johnson TN, Kerbusch T, Jones B, Tucker GT, Rostami-Hodjegan A and Milligan PA (2009) Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power. Pharm Stat Mar 16. [Epub ahead of print].Google Scholar
  34. Jones JP, Katayama JH, Jiang Y, Lee, CA, and Totah RA (2008) Identification of danazol as a selective inhibitor of cytochrome P450 2J2. Drug Metabo Rev. 40 (Suppl 3):78.Google Scholar
  35. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N and Sugiyama Y (2000a) Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 17:419–426.CrossRefPubMedGoogle Scholar
  36. Kanamitsu S, Ito K and Sugiyama Y (2000b) Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 17:336–343.CrossRefPubMedGoogle Scholar
  37. Kanamitsu SI, Ito K, Okuda H, Ogura K, Watabe T, Muro K and Sugiyama Y (2000) Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. Drug Metab Dispos 28:467–474.PubMedGoogle Scholar
  38. Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T and Sugiyama Y (2008) The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res 25:1891–1901.CrossRefPubMedGoogle Scholar
  39. Kim KA, Park PW, Hong SJ and Park JY (2008a) The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 84:236–242.CrossRefPubMedGoogle Scholar
  40. Kim KA, Park PW and Park JY (2008b) Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol 64:589–597.CrossRefPubMedGoogle Scholar
  41. Kirby BJ and Unadkat JD (2007) Grapefruit juice, a glass full of drug interactions?. Clin Pharmacol Ther 81:631–633.CrossRefPubMedGoogle Scholar
  42. Kitz R and Wilson IB (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245–3249.PubMedGoogle Scholar
  43. Kurihara A, Hagihara K, Kazui M, Ozeki T, Farid NA and Ikeda T (2005) In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metab Rev 37(Suppl 2):99.Google Scholar
  44. Lu C, Miwa G, Prakash S, Gan L and Balani S (2007) A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome P450 phenotypic data. Drug Metab Disposition 35:79–85.CrossRefGoogle Scholar
  45. Malhotra S, Bailey DG, Paine MF and Watkins PB (2001) Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 69:14–23.CrossRefPubMedGoogle Scholar
  46. McConn DJ 2nd, Lin YS, Mathisen TL, Blough DK, Xu Y, Hashizume T, Taylor SL, Thummel KE and Shuhart MC (2009) Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis. Clin Pharmacol Ther 85:387–393.CrossRefPubMedGoogle Scholar
  47. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E and Sabatine MS (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354–362.CrossRefPubMedGoogle Scholar
  48. Niemi M, Backman JT, Neuvonen M and Neuvonen PJ (2003) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46:347–351.CrossRefPubMedGoogle Scholar
  49. Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ and Backman JT (2006) Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol 62:463–472.CrossRefPubMedGoogle Scholar
  50. Obach RS, Huynh P, Allen MC and Beedham C (2004) Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:7–19.CrossRefPubMedGoogle Scholar
  51. Orlando R, De Martin S, Pegoraro P, Quintieri L and Palatini P (2009) Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function. Clin Pharmacol Ther 85:319–326.CrossRefPubMedGoogle Scholar
  52. Orlando R, Padrini R, Perazzi M, De Martin S, Piccoli P and Palatini P (2006) Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Clin Pharmacol Ther 79:489–499.CrossRefPubMedGoogle Scholar
  53. Ozdemir M, Crewe HK, Tucker GT, and Rostami-Hodjegan A (2006) The impact of ketoconazole (KTZ) dosage regimen on midazolam clearance and its prediction using PBPK modelling. Ref Type: Conference ProceedingGoogle Scholar
  54. Pang KS and Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625–653.CrossRefPubMedGoogle Scholar
  55. Pang KS, Morris ME and Sun H (2008) Formed and preformed metabolites: facts and comparisons. J Pharm Pharmacol 60:1247–1275.CrossRefPubMedGoogle Scholar
  56. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P and Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. J Am Med Assoc 300:2867–2878.CrossRefGoogle Scholar
  57. Roberts BJ, Song BJ, Soh Y, Park SS and Shoaf SE (1995) Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1. J Biol Chem 270:29632–29635.CrossRefPubMedGoogle Scholar
  58. Rodgers T, Leahy D and Rowland M (2005) Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J Pharma Sci 94:1259–1276.CrossRefGoogle Scholar
  59. Rostami-Hodjegan A and Tucker GT (2004) 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug–drug interactions. Drug Discov Today: Technol 1:441–448.CrossRefGoogle Scholar
  60. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140–148.CrossRefPubMedGoogle Scholar
  61. Rowland M, Balant L and Peck C (2004) Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS PharmSci 6:E6.CrossRefPubMedGoogle Scholar
  62. Rowland M and Matin SB (1973) Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1:553–567.CrossRefGoogle Scholar
  63. Rowland M and Tozer TN (1995) Clinical pharmacokinetics: concepts and applications. Williams and Wilkins, New York.Google Scholar
  64. Schmitt W and Willmann S (2009) Physiology-based pharmacokinetic modeling: ready to be used. Drug Discov Today: Technol 1:449–456.CrossRefGoogle Scholar
  65. Segel IH (1975) Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. John Wiley and Sons, Inc, New York.Google Scholar
  66. Shi J, Chapel S, Montay G, Hardy P, Barrett J, Sica D, Swan S, Noveck R, Leroy B and Bhargava V (2005) Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal irnpairment. Int J Clin Pharmacol Therap 43:123–133.Google Scholar
  67. Shitara Y, Hirano M, Sato H and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228–236.CrossRefPubMedGoogle Scholar
  68. Shou M, Hayashi M, Pan Y, Xu Y, Morrissey K, Xu L and Skiles GL (2008) Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos 36:2355–2370.CrossRefPubMedGoogle Scholar
  69. Sun H and Pang KS (2009) Disparity in intestine disposition between formed and preformed metabolites and implications: a theoretical study. Drug Metab Dispos 37:187–202.CrossRefPubMedGoogle Scholar
  70. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schomig A and Schomig E (2006) Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80:486–501.CrossRefPubMedGoogle Scholar
  71. Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL and Isoherranen N (2008) Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 83:77–85.CrossRefPubMedGoogle Scholar
  72. Thummel KE, Chung S, Nallani S, Reynolds KS, Strong JM, Yasuda S, Zhang L and Huang SM (2007) When is a multiple-inhibitor study necessary?. Clin Pharmacol Ther 81(Suppl 1):PII–77.Google Scholar
  73. Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H and Sugiyama Y (2001) A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res 18:1190–1202.CrossRefPubMedGoogle Scholar
  74. van Giersbergen PL, Treiber A, Schneiter R, Dietrich H and Dingemanse J (2007) Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther 81:414–419.CrossRefPubMedGoogle Scholar
  75. Vossen M, Sevestre M, Niederalt C, Jang IJ, Willmann S and Edginton AN (2007) Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor Biol Med Model 4:13.CrossRefPubMedGoogle Scholar
  76. Watanabe T, Kusuhara H, Maeda K, Shitara Y and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652–662.CrossRefPubMedGoogle Scholar
  77. Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39:1–47.PubMedGoogle Scholar
  78. Yang J, Jamei M, Yeo KR, Tucker GT and Rostami-Hodjegan A (2007) Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. Eur J Pharm Sci 31:232–241.CrossRefPubMedGoogle Scholar
  79. Yang J, Kjellsson M, Rostami-Hodjegan A and Tucker GT (2003) The effects of dose staggering on metabolic drug-drug interactions. Eur J Pharm Sci 20:223–232.CrossRefPubMedGoogle Scholar
  80. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT and Rostami-Hodjegan A (2008) Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9:384–394.CrossRefPubMedGoogle Scholar
  81. Zhang L, Zhang YD, Strong JM, Reynolds KS and Huang SM (2008) A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709–724.CrossRefPubMedGoogle Scholar
  82. Zhang X, Jones DR and Hall SD (2009) Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos 37:150–160.CrossRefPubMedGoogle Scholar
  83. Zhang Y, Zhang L, Abraham S, Apparaju S, Wu TC, Strong JM, Xiao S, Atkinson AJ, Jr., Thummel KE, Leeder JS, Lee C, Burckart GJ, Lesko LJ and Huang SM (2009) Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther 85:305–311.CrossRefPubMedGoogle Scholar
  84. Zhao P, Lee CA and Kunze KL (2007) Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A. Drug Metab Dispos 35:704–712.CrossRefPubMedGoogle Scholar
  85. Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel KE and Huang SM (2009) Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 49:351–359.CrossRefPubMedGoogle Scholar
  86. Zheng HX, Huang Y, Frassetto LA and Benet LZ (2009) Elucidating rifampin’s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther 85:78–85.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and ResearchFood and Drug AdministrationSilver SpringUSA

Personalised recommendations